REGULATION OF EMBRYO VIABILITY AND GENETIC ASSESSMENT: LEGAL LIMITS IN JAPAN

1. INTRODUCTION

Embryo viability and genetic assessment involve evaluating embryos created through in-vitro fertilisation (IVF) to identify chromosomal abnormalities, inherited genetic conditions and developmental potential before embryo transfer. The principal procedures include preimplantation genetic testing for monogenic disorders (PGT-M), aneuploidy (PGT-A) and structural rearrangements (PGT-SR).

Japan regulates these procedures primarily through professional medical guidelines and ethical oversight rather than a comprehensive embryo-testing statute. The central legal concerns include reproductive autonomy, prevention of genetic discrimination, protection of human embryos, informed consent and restrictions on non-medical embryo selection.

2. PRINCIPAL LEGAL AND REGULATORY FRAMEWORK

A. Assisted Reproductive Technology Act 2020

The Act on Assisted Reproductive Technology Offering (Act No. 76 of 2020) establishes basic principles governing assisted reproductive treatment and responsibilities of medical professionals.

It recognises IVF and embryo transfer as assisted reproductive technologies. However, it does not establish a comprehensive statutory licensing and eligibility system for every form of embryo genetic testing.

B. Japan Society of Obstetrics and Gynecology (JSOG) Guidelines

JSOG provides the principal professional framework for preimplantation genetic testing.

The 2025 revised framework distinguishes three principal categories:

PGT-M: Testing for serious hereditary diseases.

PGT-A: Testing for chromosomal numerical abnormalities.

PGT-SR: Testing for structural chromosomal rearrangements.

PGT-M requires individual assessment and appropriate genetic counselling. PGT-A is subject to eligibility criteria and institutional approval.

C. Personal Information Protection Act

The APPI regulates the handling of identifiable genetic information. Healthcare institutions must maintain appropriate confidentiality, access restrictions and security safeguards.

3. LEGAL LIMITS ON EMBRYO GENETIC ASSESSMENT

A. Medical Necessity

PGT-M is principally intended to prevent transmission of serious inherited disorders. The medical seriousness of the condition, clinical circumstances and available treatment options are relevant considerations.

B. Embryo Selection

Genetic testing should not become an unrestricted mechanism for selecting embryos according to non-medical preferences. Sex selection and selection based on preferred physical or personal characteristics raise substantial ethical concerns.

C. Genetic Counselling

Appropriate counselling should explain the purpose, limitations and possible consequences of testing. Participants should understand that genetic findings do not necessarily establish the complete future health or developmental potential of an embryo.

D. Embryo Viability

PGT-A results cannot independently establish whether an embryo will successfully implant or develop into a healthy child. Genetic assessment must therefore be distinguished from comprehensive clinical viability determination.

E. Human Embryo Research

The Act Concerning Regulation Relating to Human Cloning Techniques and other related ethical guidelines impose additional restrictions on particular embryo-related research activities. Research involving genetic modification of human fertilised embryos is subject to separate ethical controls.

4. RELEVANT JAPANESE CASE LAWS

1. Otani and Nezu Litigation (2004–2007) – Analogous Authority

Doctors and couples challenged JSOG restrictions on preimplantation genetic diagnosis before the Tokyo District Court. The plaintiffs raised reproductive autonomy and constitutional arguments. The Tokyo District Court rejected their claims in May 2007. This litigation is particularly relevant to the authority of professional medical guidelines and reproductive decision-making.

2. Supreme Court, 6 September 2006 – Posthumous Conception Case – Analogous Authority

The Supreme Court considered legal parenthood involving a child conceived using the deceased father's preserved sperm. It emphasised that complex assisted-reproduction questions require legislative consideration. The decision is relevant to the legal limits of reproductive technology.

3. Supreme Court, 23 March 2007 – Surrogacy Case – Analogous Authority

The Court addressed legal motherhood following gestational surrogacy and emphasised the importance of legislative regulation of developing reproductive technologies. Its reasoning is relevant to embryo-related reproductive arrangements.

4. Supreme Court, 12 September 2003 – Waseda University Personal Information Case – Analogous Authority

The Court recognised legal protection for identifiable personal information. This provides relevant principles for protecting genetic information obtained during embryo assessment.

5. Supreme Court, 24 December 1969 – Kyoto Gakuren Photography Case – Analogous Authority

The judgment recognised constitutional privacy interests. Its principles are relevant to protecting confidentiality in reproductive and genetic healthcare.

6. Supreme Court, 6 March 2008 – Juki Net Case – Analogous Authority

The Court considered constitutional privacy concerns associated with interconnected personal-information systems. Its reasoning is relevant to institutional management of genetic databases.

None of these judgments directly establishes a comprehensive legal test for embryo viability assessment or authorises unrestricted embryo selection.

5. INSTITUTIONAL COMPLIANCE RESPONSIBILITIES

Japanese fertility clinics and research institutions should ensure:

Compliance with applicable JSOG PGT guidelines.

Appropriate institutional ethical review.

Documented and voluntary informed consent.

Qualified genetic counselling.

Secure handling of embryo-related genetic information.

Appropriate records of testing and clinical decisions.

Restrictions on non-medical genetic selection.

Compliance with separate embryo-research requirements.

6. CONCLUSION

Japan maintains a professionally supervised and ethically restricted framework for embryo viability and genetic assessment. The Assisted Reproductive Technology Act 2020, APPI, embryo-research guidelines and JSOG standards collectively influence permissible clinical practice.

The principal legal distinction is between medically justified genetic assessment and non-medical selection of embryos. Although Japanese judicial decisions provide relevant principles concerning reproductive autonomy, privacy and legislative responsibility, direct judicial precedent specifically governing embryo viability assessment remains limited.